| NCT00628433 |
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis |
PHASE1|PHASE2 |
COMPLETED |
Harbor Therapeutics |
Ulcerative Colitis |
DRUG: Placebo|DRUG: HE3286 |
Details |
| NCT05668013 |
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease |
PHASE2 |
ACTIVE_NOT_RECRUITING |
Teva Branded Pharmaceutical Products R&D LLC |
Crohn Disease|Colitis, Ulcerative |
DRUG: TEV-48574 Dose Regimen A|DRUG: TEV-48574 Do… |
Details |
| NCT05666960 |
R-3750 in Patients With Mild to Moderate Ulcerative Colitis |
PHASE1 |
RECRUITING |
Rise Therapeutics LLC |
Ulcerative Colitis Chronic Mild|Ulcerative Coliti… |
DRUG: R-3750 |
Details |
| NCT05638347 |
A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect. |
PHASE1 |
COMPLETED |
Atridia Pty Ltd. |
Inflammatory Bowel Disease |
DRUG: HRS-7085 tablets|DRUG: Placebo tablet |
Details |
| NCT07168434 |
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome |
PHASE3 |
RECRUITING |
Biocodex |
IBS (Irritable Bowel Syndrome)|IBS-D (Diarrhea-pr… |
DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placeb… |
Details |
| NCT05611671 |
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC |
PHASE2 |
ACTIVE_NOT_RECRUITING |
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) |
Inflammatory Bowel Diseases|Colitis, Ulcerative |
DRUG: MORF-057|DRUG: Placebo |
Details |
| NCT05549323 |
A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis |
PHASE1 |
TERMINATED |
Pfizer |
Ulcerative Colitis |
DRUG: PF-07054894|DRUG: Placebo |
Details |
| NCT05536440 |
A Study to Learn About Study Medicine Called PF-07261271 in Healthy People |
PHASE1 |
COMPLETED |
Pfizer |
Healthy |
DRUG: PF-07261271|DRUG: Placebo |
Details |
| NCT05509777 |
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease |
PHASE3 |
RECRUITING |
Eli Lilly and Company |
Crohn's Disease |
DRUG: Mirikizumab |
Details |
| NCT05499130 |
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease |
PHASE2 |
COMPLETED |
Teva Branded Pharmaceutical Products R&D, Inc. |
Crohn Disease|Colitis, Ulcerative |
DRUG: TEV-48574|DRUG: Placebo |
Details |
| NCT05466890 |
Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) |
PHASE2 |
ACTIVE_NOT_RECRUITING |
Palatin Technologies, Inc |
Ulcerative Colitis|Ulcerative Colitis Acute|Ulcer… |
DRUG: PL8177 Placebo|DRUG: PL8177 |
Details |
| NCT05452304 |
AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease |
PHASE1 |
COMPLETED |
AstraZeneca |
Healthy Subjects|Crohns Disease |
BIOLOGICAL: AZD7798|BIOLOGICAL: Placebo |
Details |
| NCT05389709 |
A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting |
NULL |
COMPLETED |
Bayer |
Functional Gastrointestinal Disorders Such as Irr… |
DRUG: Iberogast (STW5-II, BAY98-7410) |
Details |
| NCT05316220 |
A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis |
PHASE3 |
WITHDRAWN |
AbbVie |
Ulcerative Colitis (UC) |
DRUG: Mesalamine|DRUG: Placebo |
Details |
| NCT05291689 |
A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC |
PHASE2 |
COMPLETED |
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) |
Inflammatory Bowel Diseases|Colitis, Ulcerative |
DRUG: MORF-057 |
Details |
| NCT05242484 |
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis |
PHASE2 |
ACTIVE_NOT_RECRUITING |
Janssen Research & Development, LLC |
Colitis, Ulcerative |
BIOLOGICAL: Guselkumab|BIOLOGICAL: Golimumab|BIOL… |
Details |
| NCT05242471 |
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease |
PHASE2 |
ACTIVE_NOT_RECRUITING |
Janssen Research & Development, LLC |
Crohn's Disease |
BIOLOGICAL: Guselkumab|BIOLOGICAL: Golimumab|BIOL… |
Details |
| NCT05239702 |
Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases |
EARLY_PHASE1 |
UNKNOWN |
Zhejiang University |
Crohn Disease|Ulcerative Colitis|Dermatomyositis|… |
BIOLOGICAL: CD7 CAR T-cells |
Details |
| NCT05180279 |
The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis |
NA |
COMPLETED |
Rush University Medical Center |
Ulcerative Colitis |
BEHAVIORAL: 7-day sleep lab |
Details |
| NCT07421011 |
Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers. |
PHASE1 |
RECRUITING |
Valenta Pharm JSC |
Irritable Bowel Syndrome|Gallstone Disease|GERD|B… |
DRUG: Trimedat® |
Details |
